Your browser doesn't support javascript.
loading
Aflatoxin levels and prevalence of TP53 aflatoxin-mutations in hepatocellular carcinomas in Mexico.
Lino-Silva, Leonardo S; Lajous, Martín; Brochier, Marion; Santiago-Ruiz, Luis; Melchor-Ruan, Javier; Xie, Yi; Wang, Mingyi; Wu, Dongjing; Higson, Herbert; Jones, Kristine; Romero-Martínez, Martin; Villalpando, Salvador; Mohar, Alejandro; Smith, Joshua W; Alvarez, Christian S; McGlynn, Katherine A; Dean, Michael; Groopman, John.
  • Lino-Silva LS; Departamento de Patología, Instituto Nacional de Cancerología. Mexico City, Mexico.. saul.lino.sil@gmail.com.
  • Lajous M; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Mexico City, Mexico. / Department of Global Health and Population, Harvard T.H. Chan School of Public Health. Boston, Massachusetts, United States. mlajous@insp.mx.
  • Brochier M; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Mexico City, Mexico.. cisp01@insp.mx.
  • Santiago-Ruiz L; Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Mexico City, Mexico.. luissantiago091@gmail.com.
  • Melchor-Ruan J; Departamento de Cirugía Oncológica, Instituto Nacional de Cancerología. Mexico City, Mexico.. dr.melchor.ruan@gmail.com.
  • Xie Y; Division of Cancer Epidemiology and Genetics, National Cancer Institute. Bethesda, Maryland, United States. yi.xie@nih.gov.
  • Wang M; Cancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research. Gaithersburg, Maryland, United States. mingyi.wang@nih.gov.
  • Wu D; Cancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research. Gaithersburg, Maryland, United States. dongjing.wu@nih.gov.
  • Higson H; Cancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research. Gaithersburg, Maryland, United States. herbert.higson@nih.gov.
  • Jones K; Cancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research. Gaithersburg, Maryland, United States. kristine.jones@nih.gov.
  • Romero-Martínez M; Center for Research in Evaluation and Surveys, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico. martin.romero@insp.mx.
  • Villalpando S; Center for Research in Nutrition and Health, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México. svillalp@insp.mx.
  • Mohar A; Unidad de Investigación Biomédica en Cáncer (Instituto de Investigaciones Biomédicas, UNAM / Dirección de Investigación, Instituto Nacional de Cancerología). Mexico City, Mexico.. alejandromohar@gmail.com.
  • Smith JW; Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University. Baltimore, United States. joshuasmith@jhu.edu.
  • Alvarez CS; Division of Cancer Epidemiology and Genetics, National Cancer Institute. Bethesda, Maryland, United States. csalvarezp@gmail.com.
  • McGlynn KA; Division of Cancer Epidemiology and Genetics, National Cancer Institute. Bethesda, Maryland, United States. mcglynnk@mail.nih.gov.
  • Dean M; Division of Cancer Epidemiology and Genetics, National Cancer Institute. Bethesda, Maryland, United States. deanm@mail.nih.gov.
  • Groopman J; Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University. Baltimore, United States. jgroopm1@jhu.edu.
Salud Publica Mex ; 64(1): 35-40, 2022 Feb 25.
Article en En | MEDLINE | ID: mdl-35438902
ABSTRACT

OBJECTIVE:

To determine the exposure to aflatoxin B1 (AFB1) in southern Mexico and the presence of the aflatoxin signature mutation in hepatocellular carcinoma (HCC) tissue from patients from a cancer referral center. MATERIALS AND

METHODS:

We estimated the prevalence and distribution of AFB1 in a representative sample of 100 women and men from Chiapas using the National Health and Nutrition Survey 2018-19. We also examined the presence of the aflatoxin signature mutation in codon 249 (R249S), and other relevant mutations of the TP53 gene in HCC tissue blocks from 24 women and 26 men treated in a national cancer referral center.

RESULTS:

The prevalence of AFB1 in serum samples was 85.5% (95%CI 72.1-93.1) and the median AFB1 was 0.117 pg/µL (IQR, 0.050-0.350). We detected TP53 R249S in three of the 50 HCCs (6.0%) and observed four other G>T transversions potentially induced by AFB1.

CONCLUSION:

Our analysis provides evidence that AFB1 may have a relevant role on HCC etiology in Mexico.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Aflatoxinas / Neoplasias Hepáticas Tipo de estudio: Prevalence_studies / Risk_factors_studies Límite: Female / Humans / Male País como asunto: Mexico Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Aflatoxinas / Neoplasias Hepáticas Tipo de estudio: Prevalence_studies / Risk_factors_studies Límite: Female / Humans / Male País como asunto: Mexico Idioma: En Año: 2022 Tipo del documento: Article